Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityDBOEY / Deutsche Boerse AG (251542106)
Institutional Owners8
Institutional Shares2,227,871
Institutional Value$ 29,510,000 USD

Institutional Stock Ownership and Shareholders()

Deutsche Boerse AG (OTC:DBOEY) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,227,871 shares. Largest shareholders include Parametric Portfolio Associates Llc, Geneva Advisors, LLC, Genesee Valley Trust Co, Canandaigua National Bank & Trust Co, Pnc Financial Services Group, Inc., Private Capital Group, Llc, Geneva Advisors, LLC, Quadrant Capital Group Llc, and Lenox Wealth Advisors, Inc..
Deutsche Boerse AG (OTC:DBOEY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-03 13F-HR CANANDAIGUA NATIONAL BANK & TRUST CO 17,515 17,455 -0.34 238 233 -2.10
2018-07-16 13F-HR Lenox Wealth Advisors, Inc. 453 6
2017-08-07 13F-HR Geneva Advisors, LLC 76,235 84,815 11.25 698 895 28.22
2018-08-13 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 1,882,061 2,091,735 11.14 25,652 27,736 8.12
2018-08-15 13F-HR GLENMEDE TRUST CO NA 1,880 0 -100.00 21 0 -100.00
2018-04-03 13F-HR GENESEE VALLEY TRUST CO 21,663 21,618 -0.21 252 289 14.68
2018-08-08 13F-HR Private Capital Group, Llc 2,906 2,906 0.00 40 38 -5.00
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 5,754 5,689 -1.13 78 76 -2.56
2017-08-07 13F-HR Geneva Advisors, LLC 84,815 2,135 -97.48 895 225 -74.86
2018-07-09 13F-HR Fisher Asset Management, LLC 24,635 0 -100.00 335 0 -100.00
2018-08-08 13F-HR QUADRANT CAPITAL GROUP LLC 975 1,065 9.23 11 12 9.09

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

UPDATE 2-Euronext CEO says sniffing for deals, but on a budget

2018-08-03 reuters
LONDON (Reuters) - Euronext (ENX.PA) is interested in making further acquisitions to move its business away from pure share trading, the exchange’s chief executive Stephane Boujnah said on Friday, as long as the price is right.

RPT-UPDATE 2-Deutsche shifts chunk of euro clearing to Frankfurt from London

2018-07-30 reuters
FRANKFURT/LONDON, July 30 (Reuters) - Deutsche Bank has begun clearing a “large part” of new euro-denominated derivatives trades in Frankfurt instead of London, a spokesman confirmed on Monday as a key Brexit battleground in financial services heats up.

Deutsche Bank shifts large part of euro clearing to Frankfurt from London

2018-07-30 reuters
FRANKFURT (Reuters) - Deutsche Bank (DBKGn.DE) has moved a “large part” of its euro clearing activity to Frankfurt from London, a spokesman confirmed on Monday.

UPDATE 1-Deutsche Bank shifts large part of euro clearing to Frankfurt from London

2018-07-30 reuters
FRANKFURT, July 30 (Reuters) - Deutsche Bank has moved a “large part” of its euro clearing activity to Frankfurt from London, a spokesman confirmed on Monday.

PRESS DIGEST- Financial Times - July 30

2018-07-30 reuters
July 30 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. (1-0)

CUSIP: 251542106